PDCD1 and lung carcinoma: Accordingly, Ajona et al. have recently demonstrated that both genetic and pharmacological inhibition of the IGF-1/IGF-1R axis enhance the antitumor activity of anti-PD-1–PD-L1 antibodies against lung cancer [16].